Company intelligence / Profile preview

PRInnovation GmbH

Düsseldorf or Cologne/Bonn region, North Rhine-Westphalia, Germanysprind.org ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

PRInnovation GmbH, a subsidiary of SPRIND, is sponsoring and managing clinical development for PRI-002, an orally available all-D peptide therapeutic targeting neurotoxic protein aggregates in Alzheimer’s disease. The company has completed Phase I trials demonstrating safety and tolerability. As of February 2025, recruitment for the multicenter Phase II study (PRImus-AD) was successfully completed with 304 patients enrolled across six European countries. Results are expected in late 2026; if positive, a pivotal Phase III trial will be planned with a pharmaceutical partner

Therapeutic areas: Neurology
Modalities: All-D peptide therapeutics
Industry: Biotech

Partnerships

Priavoid GmbHSPRIND

Beyond the preview

Go deeper on PRInnovation GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRInnovation GmbH.